Immunocore (NASDAQ: IMCR) has recently received a number of price target changes and ratings updates:
- 7/20/2026 – Immunocore was upgraded by Wall Street Zen from “hold” to “buy”.
- 7/13/2026 – Immunocore had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 7/12/2026 – Immunocore was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/7/2026 – Immunocore was downgraded by Zacks Research from “strong-buy” to “hold”.
Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.
The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.
Featured Stories
- Five stocks we like better than Immunocore
- 3 Medical Device Stocks Giving Investors a Different Healthcare Play
- Cybersecurity Stocks Are Holding Up as the AI Trade Starts to Crack
- Bank Earnings Are Roaring, But Wall Street Isn’t Ready to Celebrate
- Buyback Boom: These 3 Companies Are Betting Billions on Their Own Stocks
Receive News & Ratings for Immunocore Holdings PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore Holdings PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
